Last week, the US Supreme Court issued a long-awaited decision in Myriad Genetics, which sent shockwaves through the very foundation of the biotech industry
Konstantin Linnik
Advertisement
Articles by Konstantin Linnik
Advertisement
Latest Updated Articles
- The Myriad Ruling: Six Points Every Biotech CEO Must Consider
Published: June 19th 2013 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Study Claims Ozempic Lowers Biological Age
3
GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate
4
How will DTC Programs Impact PBMs?
5
